Scientifically Credible, User-Friendly Economic Models

Having developed more than 100 economic models over the past decade, Xcenda is broadly recognized as a leader in both the development of economic models and new modeling methodologies. Are you considering partnering with us? Here are a few quick reasons why we think you should:

  • We simplify complex disease states and methodologies (including Markov models) into user-friendly economic models that payers understand and trust 

  • Payers recognize Xcenda as a source of scientifically credible and methodologically sound models that are also easy to use

  • Our unique and easy-to-use features help account managers or other managed markets professionals more effectively demonstrate burden of disease and/or a product's economic value proposition

  • We understand the broad application of Section 114 as it relates to the development and deployment of economic models

  • As a full-service consultancy, we deliver more value by helping clients develop a product value strategy, produce an AMCP dossier, conduct a retrospective database analysis, or address reimbursement challenges

  • Many highly satisfied clients repeatedly engage our services because we meet their timelines while producing high-quality deliverables

Xcenda provides the following types of economic models:

Cost-effectiveness Models

Leverage your product’s value story with the development of a cost-effectiveness model in Excel or TreeAge. Cost-effectiveness models compare the value of pharmaceuticals, medical devices, procedures, or diagnostics by quantifying the cost per unit of effectiveness. More expensive and more effective products can be shown to provide good value for the money. Xcenda’s modeling team can design and develop a model to support your product’s unique value story. We have experience developing everything from simple decision tree models to complex Markov models. We can also assist you in developing a strategy to communicate your product’s value story through presentations and publication of abstracts, posters, and manuscripts. 

Budget Impact Models

If you have a new drug coming to market (or a new indication), then you need an AMCP dossier and a budget impact model. Budget impact models quantify the cost of a new drug to managed care payers. Xcenda’s modeling team can help you design a budget impact model that captures all the economic benefits of your product, including reduced administration costs, medical cost offsets, and reductions in adverse event rates. We can meet your timeline requirements for Excel budget impact models for use in your dossier, complete with enhanced graphics, navigation, and macros to provide payers a credible and user-friendly model.

Disease Burden Models

If you are first to market in a disease state that payers know little about, then you need a disease burden model to quantify the clinical and economic burden of the disease. Xcenda’s modeling team can help you put a disease on the radar screen of payers by showing them the full economic costs associated with the disease. These costs represent the potential economic benefits due to the introduction of improved therapies to treat the disease. We can help you publish the results from a disease burden model to communicate the existing clinical and economic burden of the disease and the potential benefits of therapy through the publication of abstracts, posters, and manuscripts.

Pre-Conference Workshop

Unveiling the Mysteries of Pharmacoeconomic Models:   A Look at the Methods, Data Sources, and Applications.

  • Held in conjunction with AMCP’S 22nd Annual Meeting & Showcase

How can we help?

What our clients are saying...

"I am very pleased with the fantastic job Xcenda's health outcomes team has done in conceptualizing and executing the development of the model with technical rigor. Your team explored many of our key opinion leader's ideas and directions while still completing the model on-time. Keep up the good work, guys. I'll look forward to continued partnership with Xcenda."

Senior Director, Global Health Economics, medical device firm